Skip to main content
BVS logo

BVS

Bioventus Inc.
$11.88 -0.34 (-2.78%) At close · Jul 10
Market Cap
$992.39M
Shares
83,534,785

Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.

Revenue
$568.09M -0.9%
FY2025 Revenue FY2021–FY2025
Net Income
$22.73M +167.8%
FY2025 Net Income FY2021–FY2025
Gross Margin
68.33% +0.6pp
FY2025 Gross Margin FY2021–FY2025
Operating Margin
9.5% +11.6pp
FY2025 Operating Margin FY2021–FY2025
Diluted EPS
$0.33 +163.5%
FY2025 Diluted EPS FY2021–FY2025
Operating Cash Flow
$74.67M +92.5%
FY2025 Operating Cash Flow FY2021–FY2025

Chart any reported metric, KPI or segment over time — the full statement history lives here

Line Item FY2026 (G) TTM FY2025 FY2024 FY2023 FY2022 FY2021
$600M – $610M $576.3M $568.09M $573.28M $512.35M $512.12M $430.9M
$180.43M $179.93M $185.05M $184.15M $181.04M $128.19M
$395.87M $388.16M $388.23M $328.19M $331.08M $302.71M
68.33% 67.72% 64.06% 64.65% 70.25%
$11.57M $12.11M $13.64M $13.45M $25.94M $19.04M
$318.85M $314.03M $340.89M $303.88M $332.61M $254.25M
$38.98M $39.02M $45.24M $67.04M $35.48M
$46.35M $47.01M $49.56M $57.37M $66.8M $34.88M
$2.24M -$52K $840K $6.78M $2.49M
$57.52M $53.98M -$11.98M -$81.73M -$251.05M $12.06M
9.5% -2.09% -15.95% -49.02% 2.8%
$103.87M $100.99M $37.58M -$24.36M -$184.25M $46.94M
-$23.88M -$28.27M -$37.15M -$39.39M -$12.85M -$4.44M
$33.64M $25.71M -$49.13M -$121.11M -$263.9M $7.62M
-$899K -$1.57M -$5.29M $85K -$50.51M -$1.97M
$28.48M $22.73M -$33.54M -$156.23M -$158.7M $19.38M
4% -5.85% -30.49% -30.99% 4.5%
-$10.92M -$54.69M -$9.79M
-$158.7M
$28.27M $23.41M -$36.91M -$155.33M -$158.99M $18.12M
USD/shares $0.34 -$0.52 -$2.49 -$2.59 -$0.15
USD/shares $0.33 -$0.52 -$2.49 -$2.59 -$0.15
shares 66.62M 64.55M 62.65M 61.39M 45.47M
shares 68.91M 64.55M 62.65M 61.39M 45.47M
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.

Price & Valuation

Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.

Valuation

EV/Revenue
2.13×
Medical Devices median 2.38×
EV/EBIT
21.36×
Medical Devices median 21.54×
P/E (TTM)
28.98×
Medical Devices median 26.77×

Valuation over time computed as of each quarter's filing date

Revenue Breakdown

Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.

Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.

By Segment (USD)

Component 2025-12-31 2024-12-31 2023-12-31 2022-12-31
US Segment $502,097,000 $506,809,000 $449,860,000 $455,251,000
International Segment $65,990,000 $66,471,000 $62,485,000 $56,866,000

By Geography (USD)

Component 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
United States $502,097,000 $506,809,000 $449,860,000 $455,251,000 $387,553,000 $293,697,000 $305,072,000
Non Us $65,990,000 $66,471,000 $62,485,000 $56,866,000 $43,345,000 $27,464,000 $35,069,000

By Product & Service (USD)

Component 2021-12-31 2020-12-31 2019-12-31
Pain Treatments $221,607,000 $171,178,000 $182,082,000
Restorative Therapies $121,572,000 $88,624,000 $103,504,000
Surgical Solutions $87,719,000 $61,359,000 $54,555,000
Key facts CIK 1665988 CUSIP 09075A108 13F (30d) 2 filings 2 filers Visit website Investor relations